• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Neurocrine Biosciences Inc.

    3/6/25 2:09:22 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $NBIX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 9)


    Neurocrine Biosciences Inc

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    64125C109

    (CUSIP Number)


    02/28/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    64125C109


    1Names of Reporting Persons

    The Vanguard Group
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    66,089.00
    7Sole Dispositive Power

    9,976,666.00
    8Shared Dispositive Power

    153,021.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    10,129,687.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    10.15 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Neurocrine Biosciences Inc
    (b)Address of issuer's principal executive offices:

    12780 El Camino Real, San Diego, CA, 92130
    Item 2. 
    (a)Name of person filing:

    The Vanguard Group
    (b)Address or principal business office or, if none, residence:

    100 Vanguard Blvd., Malvern, PA 19355
    (c)Citizenship:

    PA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    64125C109
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    10129687
    (b)Percent of class:

    10.15  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    66089

     (iii) Sole power to dispose or to direct the disposition of:

    9976666

     (iv) Shared power to dispose or to direct the disposition of:

    153021

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Vanguard Group
     
    Signature:Ashley Grim
    Name/Title:Head of Global Fund Administration
    Date:03/06/2025
    Get the next $NBIX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NBIX

    DatePrice TargetRatingAnalyst
    1/8/2026$175.00Overweight → Equal-Weight
    Morgan Stanley
    10/21/2025$175.00Buy
    Citigroup
    7/21/2025$163.00Buy
    Truist
    7/10/2025$182.00Buy
    Goldman
    4/15/2025$138.00Hold → Buy
    Needham
    4/14/2025$137.00Sector Perform → Outperform
    RBC Capital Mkts
    2/11/2025$138.00Hold
    Deutsche Bank
    10/10/2024$155.00Outperform
    Raymond James
    More analyst ratings

    $NBIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Corp. Affairs Officer Boyer David W. converted options into 2,096 shares and covered exercise/tax liability with 1,189 shares, increasing direct ownership by 24% to 4,713 units (SEC Form 4)

    4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)

    2/3/26 6:22:45 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Commercial Officer Benevich Eric converted options into 2,294 shares and covered exercise/tax liability with 1,292 shares, increasing direct ownership by 2% to 52,755 units (SEC Form 4)

    4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)

    2/3/26 6:21:32 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Abernethy Matt converted options into 2,437 shares and covered exercise/tax liability with 1,368 shares, increasing direct ownership by 3% to 37,097 units (SEC Form 4)

    4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)

    2/3/26 6:06:21 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NBIX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026

    Total Fourth-Quarter and Full-Year 2025 Net Product Sales of $798.3 Million and $2.83 Billion, Representing Year-Over-Year Growth of 29% and 22%, Respectively INGREZZA® (valbenazine) Full Year 2026 Net Product Sales Guidance of $2.7 - $2.8 Billion SAN DIEGO, Feb. 11, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the fourth quarter ended December 31, 2025. "Our 2025 performance reflects the strength and durability of our commercial business and meaningful progress we are making transforming Neurocrine into a broader, m

    2/11/26 4:01:00 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia

    SAN DIEGO, Jan. 26, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1065890 in adults with tardive dyskinesia (TD). NBI-1065890 is a next-generation, selective inhibitor of the vesicular monoamine transporter 2 (VMAT2). Building on nearly 20 years of deep scientific expertise and experience in VMAT2 inhibition, Neurocrine designed NBI-1065890 to potentially deliver a differentiated profile, including the possibility of longer-acting options for the treatment of TD. "NBI

    1/26/26 8:30:00 AM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results

    Conference Call and Webcast Scheduled for Wednesday, February 11 SAN DIEGO, Jan. 21, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it has scheduled its fourth quarter and year-end 2025 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on February 11, 2026. The schedule for the press release and conference call / webcast is as follows: Q4 and Year-End 2025 Press Release: February 11, 2026 at 1:00 p.m. PT / 4:00 p.m. ETQ4 and Year-End 2025 Conference Call: February 11, 2026 at 1:30 p.m. PT / 4

    1/21/26 4:01:00 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NBIX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 13, 2024 - FDA Approves New Treatment for Congenital Adrenal Hyperplasia

    For Immediate Release: December 13, 2024 Today, the U.S. Food and Drug Administration approved Crenessity (crinecerfont) to be used together with glucocorticoids (steroids) to control androgen (a testosterone-like hormone) levels in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH).“Today’s approval provides an important advance for patients with classic con

    12/13/24 5:54:17 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NBIX
    SEC Filings

    View All

    SEC Form 10-K filed by Neurocrine Biosciences Inc.

    10-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)

    2/11/26 4:03:36 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Neurocrine Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)

    2/11/26 4:02:00 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13G filed by Neurocrine Biosciences Inc.

    SCHEDULE 13G - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)

    1/21/26 8:13:39 AM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NBIX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Neurocrine Biosciences downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Neurocrine Biosciences from Overweight to Equal-Weight and set a new price target of $175.00

    1/8/26 8:41:09 AM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Citigroup initiated coverage on Neurocrine Biosciences with a new price target

    Citigroup initiated coverage of Neurocrine Biosciences with a rating of Buy and set a new price target of $175.00

    10/21/25 7:21:11 AM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Truist initiated coverage on Neurocrine Biosciences with a new price target

    Truist initiated coverage of Neurocrine Biosciences with a rating of Buy and set a new price target of $163.00

    7/21/25 8:37:42 AM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NBIX
    Leadership Updates

    Live Leadership Updates

    View All

    Neurocrine Biosciences Appoints Mike Sibley as Senior Vice President, General Manager of Neuropsychiatry Franchise

    SAN DIEGO, Oct. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the appointment of Mike Sibley as Senior Vice President and General Manager of the company's Neuropsychiatry franchise. Sibley, a proven leader with more than 20 years of commercial experience in the biopharmaceutical industry, will be responsible for developing and executing the sales and marketing strategy for Neurocrine's neuropsychiatry products, including the INGREZZA® franchise. "Mike is an accomplished leader with a strong record of leading high-performing sales and market

    10/6/25 4:05:00 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer

    SAN DIEGO, June 9, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the appointment of Lewis Choi as Chief Information Officer, effective June 9, 2025. Choi, an accomplished leader with 25 years of experience in information technology and artificial intelligence, will be responsible for driving the vision and long-term strategic direction of the company's technology initiatives. "Lewis is a proven global healthcare leader with a track record of utilizing technology to drive both cultural and technological change," said Matt Abernethy, Chief Finan

    6/9/25 4:05:00 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

    SAN DIEGO, May 30, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, today announced the appointment of Matthew Abernethy, M.B.A., to its Board of Directors effective as of May 29, 2025. Mr. Abernethy brings to the Company over 15 years' experience in corporate finance and investor relations in the biotech and medical device industry. In addition, the Company announced that Timothy P. Coughlin stepped down from the Board of Directors, effective concurrently with Mr. Abernethy's appointment. "Mr. Aberne

    5/30/25 4:30:14 PM ET
    $FATE
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NBIX
    Financials

    Live finance-specific insights

    View All

    Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026

    Total Fourth-Quarter and Full-Year 2025 Net Product Sales of $798.3 Million and $2.83 Billion, Representing Year-Over-Year Growth of 29% and 22%, Respectively INGREZZA® (valbenazine) Full Year 2026 Net Product Sales Guidance of $2.7 - $2.8 Billion SAN DIEGO, Feb. 11, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the fourth quarter ended December 31, 2025. "Our 2025 performance reflects the strength and durability of our commercial business and meaningful progress we are making transforming Neurocrine into a broader, m

    2/11/26 4:01:00 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results

    Conference Call and Webcast Scheduled for Wednesday, February 11 SAN DIEGO, Jan. 21, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it has scheduled its fourth quarter and year-end 2025 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on February 11, 2026. The schedule for the press release and conference call / webcast is as follows: Q4 and Year-End 2025 Press Release: February 11, 2026 at 1:00 p.m. PT / 4:00 p.m. ETQ4 and Year-End 2025 Conference Call: February 11, 2026 at 1:30 p.m. PT / 4

    1/21/26 4:01:00 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Neurocrine Biosciences Reports Third Quarter 2025 Financial Results

    Achieved Total Net Product Sales of $790 Million Representing 28% Year-Over-Year Growth INGREZZA® (valbenazine) Third-Quarter 2025 Net Product Sales of $687 Million Representing 12% Year-Over-Year Growth CRENESSITY® (crinecerfont) Third-Quarter 2025 Net Product Sales of $98 Million with 540 Total New Patient Enrollment Start Forms SAN DIEGO, Oct. 28, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the third quarter ended September 30, 2025. "Neurocrine's third quarter commercial results highlight the meaningful impact t

    10/28/25 4:01:00 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NBIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Neurocrine Biosciences Inc.

    SC 13G - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)

    10/17/24 9:54:01 AM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Neurocrine Biosciences Inc. (Amendment)

    SC 13G/A - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)

    2/9/23 11:27:44 AM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Neurocrine Biosciences Inc. (Amendment)

    SC 13G/A - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)

    2/14/22 2:34:19 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care